Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application
May 04, 2021 08:00 ET | Source: Sunshine Biopharma Inc. Sunshine Biopharma Inc. Montreal, Quebec, CANADA
MONTREAL, May 04, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19 treatment under development. Sunshine had originally filed a provisional patent application covering the COVID-19 treatment on May 22, 2020. This priority date has been maintained in the newly filed PCT application.
Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033
March 11, 2021 09:00 ET | Source: Sunshine Biopharma Inc. Sunshine Biopharma Inc. Montreal, Quebec, CANADA
MONTREAL, March 11, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until 2033. The Canadian Intellectual Property recently i